Sarepta Therapeutics (Brazil) Today
| S1RP34 Stock | BRL 40.08 0.39 0.96% |
Performance3 of 100
| Odds Of DistressLess than 22
|
Sarepta Therapeutics is trading at 40.08 as of the 3rd of December 2024, a 0.96% down since the beginning of the trading day. The stock's open price was 40.47. Sarepta Therapeutics has about a 22 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Sarepta Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 3rd of November 2024 and ending today, the 3rd of December 2024. Click here to learn more.
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. Sarepta Therapeutics, Inc. The company has 1.76 B outstanding shares. More on Sarepta Therapeutics
Moving against Sarepta Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Sarepta Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Sarepta Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Sarepta Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Sarepta Therapeutics (S1RP34) is traded on Sao Paulo Exchange in Brazil and employs 840 people. The company currently falls under 'Large-Cap' category with a current market capitalization of 58.46 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Sarepta Therapeutics's market, we take the total number of its shares issued and multiply it by Sarepta Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Sarepta Therapeutics operates under Healthcare sector and is part of Biotechnology industry. The entity has 1.76 B outstanding shares.
Sarepta Therapeutics has accumulated about 1.74 B in cash with (443.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 21.78.
Check Sarepta Therapeutics Probability Of Bankruptcy
Sarepta Therapeutics Risk Profiles
Although Sarepta Therapeutics' alpha and beta are two of the key measurements used to evaluate Sarepta Therapeutics' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.55 | |||
| Semi Deviation | 1.84 | |||
| Standard Deviation | 3.34 | |||
| Variance | 11.17 |
Sarepta Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Sarepta Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Funds Screener Now
Funds ScreenerFind actively-traded funds from around the world traded on over 30 global exchanges |
| All Next | Launch Module |
Sarepta Therapeutics Corporate Management
Elected by the shareholders, the Sarepta Therapeutics' board of directors comprises two types of representatives: Sarepta Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sarepta. The board's role is to monitor Sarepta Therapeutics' management team and ensure that shareholders' interests are well served. Sarepta Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sarepta Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| William Ciambrone | Ex Operations | Profile | |
| Dallan Murray | VP Officer | Profile | |
| Ian Estepan | Ex CFO | Profile | |
| Douglas Esq | CEO Pres | Profile | |
| Alison Nasisi | Chief VP | Profile | |
| Bilal Arif | VP Operations | Profile | |
| Diane Berry | Sr Affairs | Profile |
Additional Information and Resources on Investing in Sarepta Stock
When determining whether Sarepta Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Sarepta Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Sarepta Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Sarepta Therapeutics Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sarepta Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Sarepta Stock refer to our How to Trade Sarepta Stock guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.